Covered recipient · General Payments record
MARCY J FLECKER
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$3,344.27
228 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,344.27 | 228 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARCY J FLECKER
NPI 1508875774 · CMS profile ID 691345
Allopathic & Osteopathic Physicians / Family Medicine
SMITHFIELD, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MARCY J FLECKER, NPI 1508875774, CMS profile ID 691345, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 228 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508875774?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
228 matching records · $3,344.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 228.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals USA | $14.33 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 808542443 | CMS |
| AbbVie Inc. | $9.82 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480419 | CMS |
| Novo Nordisk Inc | $17.55 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811690431 | CMS |
| RedHill Biopharma Inc. | $13.33 | 06/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799921433 | CMS |
| GlaxoSmithKline, LLC. | $13.10 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802291181 | CMS |
| Astellas Pharma US Inc | $17.05 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821321851 | CMS |
| Novo Nordisk Inc | $16.09 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811137886 | CMS |
| Janssen Pharmaceuticals, Inc | $12.67 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788331727 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.67 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829498427 | CMS |
| Amarin Pharma Inc. | $20.82 | 06/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815107055 | CMS |
| Lilly USA, LLC | $8.65 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818585465 | CMS |
| Biohaven Pharmaceuticals, Inc. | $14.01 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852491113 | CMS |
| Ironwood Pharmaceuticals, Inc | $19.65 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855109675 | CMS |
| Novo Nordisk Inc | $19.61 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810638069 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.23 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819926739 | CMS |
| GlaxoSmithKline, LLC. | $13.51 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802741969 | CMS |
| Janssen Pharmaceuticals, Inc | $10.66 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788331745 | CMS |
| Novo Nordisk Inc | $17.12 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810767083 | CMS |
| PFIZER INC. | $17.47 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833496475 | CMS |
| Biohaven Pharmaceuticals, Inc. | $5.28 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852491111 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.56 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763450632 | CMS |
| AbbVie Inc. | $7.78 | 05/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480415 | CMS |
| Novo Nordisk Inc | $15.08 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811442711 | CMS |
| Novo Nordisk Inc | $15.08 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811690427 | CMS |
| AbbVie Inc. | $13.64 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480411 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.75 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829710693 | CMS |
| GlaxoSmithKline, LLC. | $13.09 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801577131 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.30 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850413085 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.11 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819926737 | CMS |
| RedHill Biopharma Inc. | $17.46 | 05/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799921431 | CMS |
| Janssen Pharmaceuticals, Inc | $12.67 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788331747 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10.60 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763450634 | CMS |
| Ironwood Pharmaceuticals, Inc | $19.34 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855109673 | CMS |
| Teva Pharmaceuticals USA, Inc. | $23.48 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839714845 | CMS |
| Amarin Pharma Inc. | $16.49 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815107065 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.38 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763789152 | CMS |
| Lilly USA, LLC | $19.72 | 05/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818585463 | CMS |
| PFIZER INC. | $16.38 | 05/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833464209 | CMS |
| AbbVie Inc. | $4.70 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480407 | CMS |
| Lilly USA, LLC | $16.44 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818632393 | CMS |
| Biohaven Pharmaceuticals, Inc. | $12.48 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852491109 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.65 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763450636 | CMS |
| GlaxoSmithKline, LLC. | $12.39 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803083801 | CMS |
| AbbVie Inc. | $20.80 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480403 | CMS |
| Amarin Pharma Inc. | $18.50 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815113567 | CMS |
| GlaxoSmithKline, LLC. | $8.03 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802697922 | CMS |
| GlaxoSmithKline, LLC. | $7.62 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802855425 | CMS |
| Novo Nordisk Inc | $16.79 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810638065 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.69 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819926735 | CMS |
| AbbVie Inc. | $18.99 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794480399 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,361,760.66 | 151 |
| PY2024 | Principal investigator | $1,248,049.16 | 184 |
| PY2023 | Principal investigator | $1,661,032.99 | 154 |
| PY2022 | Recipient | $1,240.00 | 1 |
| PY2022 | Principal investigator | $624,324.25 | 141 |
| PY2021 | Recipient | $4,735.66 | 1 |
| PY2021 | Principal investigator | $455,969.90 | 140 |
| PY2020 | Principal investigator | $640,013.50 | 180 |
| PY2019 | Principal investigator | $912,016.56 | 121 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
151 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $715.76 | 12/31/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age | No dispute reported | 06/30/2026 | 1202532428 |
| Principal investigator 1 | ABBVIE INC. | $582.00 | 12/31/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine | No dispute reported | 06/30/2026 | 1202532430 |
| Principal investigator 1 | ABBVIE INC. | $772.50 | 12/31/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) with a 24-week Open-label Treatment Extension | No dispute reported | 06/30/2026 | 1202533543 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202533735 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 12/24/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607750 |
| Principal investigator 1 | Genentech, Inc. | $450.00 | 12/24/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607758 |
| Principal investigator 1 | ABBVIE INC. | $2,631.55 | 12/18/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202531294 |
| Principal investigator 1 | PFIZER INC. | $17,861.87 | 12/17/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228744172 |
| Principal investigator 1 | PFIZER INC. | $21,361.06 | 12/16/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228748969 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 12/15/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211607313 |
| Principal investigator 1 | ABBVIE INC. | $330.75 | 12/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202530186 |
| Principal investigator 1 | ABBVIE INC. | $2,854.58 | 12/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202530190 |
| Principal investigator 1 | ABBVIE INC. | $820.00 | 12/10/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202529880 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,635.00 | 12/10/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185548659 |
| Principal investigator 1 | OraSure Technologies Inc. | $520.00 | 12/05/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792142 |
| Principal investigator 1 | OraSure Technologies Inc. | $250.00 | 12/05/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792144 |
| Principal investigator 1 | OraSure Technologies Inc. | $500.00 | 12/05/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792146 |
| Principal investigator 1 | OraSure Technologies Inc. | $1,150.00 | 12/05/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792198 |
| Principal investigator 1 | ABBVIE INC. | $3,090.00 | 12/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202528342 |
| Principal investigator 1 | ABBVIE INC. | $263.25 | 12/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202528344 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 12/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202528364 |
| Principal investigator 1 | Ardelyx, Inc. | $2,353.75 | 12/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838864 |
| Principal investigator 1 | Genentech, Inc. | $35,002.00 | 12/01/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607754 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,027.22 | 11/21/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) | No dispute reported | 06/30/2026 | 1185548653 |
| Principal investigator 1 | OraSure Technologies Inc. | $1,000.00 | 11/21/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792194 |
| Principal investigator 1 | OraSure Technologies Inc. | $400.00 | 11/21/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792196 |
| Principal investigator 1 | PFIZER INC. | $148.60 | 11/13/2025 | Non-covered Recipient Entity Frontier Clinical Res LLC | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228719523 |
| Principal investigator 1 | PFIZER INC. | $117.00 | 11/13/2025 | Non-covered Recipient Entity Frontier Clinical Res LLC | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228723908 |
| Principal investigator 1 | PFIZER INC. | $5,143.50 | 11/13/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228737493 |
| Principal investigator 1 | Ardelyx, Inc. | $923.25 | 11/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838820 |
| Principal investigator 1 | OraSure Technologies Inc. | $3,000.00 | 11/07/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792192 |
| Principal investigator 1 | ABBVIE INC. | $3,090.00 | 11/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202521327 |
| Principal investigator 1 | PFIZER INC. | $5,975.45 | 11/05/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228737481 |
| Principal investigator 1 | Ardelyx, Inc. | $1,555.25 | 11/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838779 |
| Principal investigator 1 | Ardelyx, Inc. | $715.25 | 11/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838786 |
| Principal investigator 1 | OraSure Technologies Inc. | $360.00 | 10/31/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792190 |
| Principal investigator 1 | ABBVIE INC. | $2,976.75 | 10/28/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202518809 |
| Principal investigator 1 | Eli Lilly and Company | $3,251.37 | 10/28/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) | No dispute reported | 06/30/2026 | 1187881758 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $182,872.75 | 10/27/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190310494 |
| Principal investigator 1 | ABBVIE INC. | $850.00 | 10/23/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202518381 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 10/22/2025 | Non-covered Recipient Entity Frontier Clinical Research | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A BNT162B2 LP81ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID19 | No dispute reported | 06/30/2026 | 1228723078 |
| Principal investigator 1 | ABBVIE INC. | $3,334.62 | 10/16/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202517299 |
| Principal investigator 1 | OraSure Technologies Inc. | $6,000.00 | 10/10/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792124 |
| Principal investigator 1 | OraSure Technologies Inc. | $1,020.00 | 10/10/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792162 |
| Principal investigator 1 | ABBVIE INC. | $5,085.00 | 10/09/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202515851 |
| Principal investigator 1 | Ardelyx, Inc. | $923.25 | 10/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838643 |
| Principal investigator 1 | Ardelyx, Inc. | $437.50 | 10/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838646 |
| Principal investigator 1 | Eli Lilly and Company | $720.00 | 10/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187882426 |
| Principal investigator 1 | Eli Lilly and Company | $219,172.00 | 09/29/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187882424 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,475.25 | 09/17/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185548655 |
| Principal investigator 1 | ABBVIE INC. | $2,933.75 | 09/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202510688 |
| Principal investigator 1 | ABBVIE INC. | $124.75 | 09/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202510690 |
| Principal investigator 1 | ABBVIE INC. | $2,900.00 | 09/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202510692 |
| Principal investigator 1 | ABBVIE INC. | $1,090.58 | 09/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202510694 |
| Principal investigator 1 | Ardelyx, Inc. | $1,650.25 | 09/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838593 |
| Principal investigator 1 | ABBVIE INC. | $2,900.00 | 09/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202510178 |
| Principal investigator 1 | ABBVIE INC. | $2,970.00 | 09/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202509244 |
| Principal investigator 1 | ABBVIE INC. | $2,900.00 | 09/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202509246 |
| Principal investigator 1 | Ardelyx, Inc. | $840.25 | 09/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838583 |
| Principal investigator 1 | Ardelyx, Inc. | $1,370.25 | 08/18/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838561 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,054.03 | 08/15/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192110795 |
| Principal investigator 1 | OraSure Technologies Inc. | $4,500.00 | 08/08/2025 | Non-covered Recipient Entity Frontier Clinical Research | Clinical Sample Collection and Testing Protocol | No dispute reported | 06/30/2026 | 1248792090 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $85,387.90 | 08/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185548657 |
| Principal investigator 1 | ABBVIE INC. | $5,670.00 | 08/06/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202502598 |
| Principal investigator 1 | Ardelyx, Inc. | $930.25 | 08/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838510 |
| Principal investigator 1 | Ardelyx, Inc. | $875.00 | 08/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838514 |
| Principal investigator 1 | ABBVIE INC. | $3,817.62 | 07/24/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202499648 |
| Principal investigator 1 | PFIZER INC. | $393.53 | 07/11/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228789933 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 07/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202497378 |
| Principal investigator 1 | ABBVIE INC. | $2,970.00 | 07/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202496211 |
| Principal investigator 1 | Genentech, Inc. | $9,298.00 | 07/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607673 |
| Principal investigator 1 | Ardelyx, Inc. | $1,370.25 | 07/01/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838442 |
| Principal investigator 1 | Eli Lilly and Company | $352.48 | 06/24/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187883730 |
| Principal investigator 1 | Genentech, Inc. | $6,860.00 | 06/23/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607627 |
| Principal investigator 1 | PFIZER INC. | $8,868.23 | 06/21/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775796 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,396.40 | 06/18/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172419 |
| Principal investigator 1 | Ardelyx, Inc. | $715.25 | 06/09/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838405 |
| Principal investigator 1 | PFIZER INC. | $21,516.41 | 06/06/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228722712 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $24,025.00 | 06/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185548663 |
| Principal investigator 1 | Genentech, Inc. | $2,596.00 | 05/28/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607584 |
| Principal investigator 1 | ABBVIE INC. | $587.23 | 05/22/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202485779 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $8,892.21 | 05/19/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187882428 |
| Principal investigator 1 | Ardelyx, Inc. | $1,500.00 | 05/12/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838361 |
| Principal investigator 1 | ABBVIE INC. | $4,400.00 | 05/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202484297 |
| Principal investigator 1 | ABBVIE INC. | $16,450.00 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202482487 |
| Principal investigator 1 | Genentech, Inc. | $1,298.00 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607571 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607592 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $896.00 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192170348 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,286.60 | 05/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172391 |
| Principal investigator 1 | ABBVIE INC. | $2,650.05 | 05/06/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202481383 |
| Principal investigator 1 | Ardelyx, Inc. | $3,089.00 | 05/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838333 |
| Principal investigator 1 | Ardelyx, Inc. | $965.25 | 05/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838345 |
| Principal investigator 1 | Genentech, Inc. | $2,487.90 | 04/29/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211607302 |
| Principal investigator 1 | PFIZER INC. | $64,791.92 | 04/29/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228779378 |
| Principal investigator 1 | Genentech, Inc. | $5,192.00 | 04/25/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607575 |
| Principal investigator 1 | Genentech, Inc. | $29,204.00 | 04/25/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607588 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 04/23/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172404 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $937.50 | 04/23/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172415 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 04/21/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211607297 |
| Principal investigator 1 | PFIZER INC. | $86.34 | 04/15/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228770186 |
| Principal investigator 1 | OraSure Technologies Inc. | $1,750.00 | 04/14/2025 | Non-covered Recipient Entity Frontier Clinical Research | Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use | No dispute reported | 06/30/2026 | 1248792236 |
| Principal investigator 1 | Genentech, Inc. | $1,298.00 | 04/11/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607619 |
| Principal investigator 1 | PFIZER INC. | $37,145.25 | 04/10/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228794073 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $325.00 | 04/09/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172396 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,500.00 | 04/09/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172400 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $625.00 | 04/09/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172413 |
| Principal investigator 1 | Ardelyx, Inc. | $2,423.25 | 04/08/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838241 |
| Principal investigator 1 | Genentech, Inc. | $2,596.00 | 04/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607633 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,445.20 | 04/04/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192170357 |
| Principal investigator 1 | ABBVIE INC. | $472.50 | 04/03/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202471748 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,150.00 | 04/02/2025 | Non-covered Recipient Entity LONG ISLAND REGIONAL ARTHRITIS AND OSTEOPOROSIS CARE, PC | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185548661 |
| Principal investigator 1 | Genentech, Inc. | $2,596.00 | 04/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607562 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 04/01/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202467878 |
| Principal investigator 1 | PFIZER INC. | $1,456.65 | 04/01/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228797167 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $54,147.18 | 03/31/2025 | Non-covered Recipient Entity MONTGOMERY MEDICAL | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190304221 |
| Principal investigator 1 | OraSure Technologies Inc. | $950.00 | 03/31/2025 | Non-covered Recipient Entity Frontier Clinical Research | Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use | No dispute reported | 06/30/2026 | 1248792206 |
| Principal investigator 1 | PFIZER INC. | $125.38 | 03/28/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775525 |
| Principal investigator 1 | ABBVIE INC. | $675.00 | 03/27/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202466738 |
| Principal investigator 1 | Genentech, Inc. | $7,644.00 | 03/26/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607441 |
| Principal investigator 1 | Eli Lilly and Company | $14,922.00 | 03/25/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187882724 |
| Principal investigator 1 | Genentech, Inc. | $9,086.00 | 03/21/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607411 |
| Principal investigator 1 | Genentech, Inc. | $2,512.10 | 03/20/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A phase IIIB surveillance study of susceptibility to baloxavir marboxil | No dispute reported | 06/30/2026 | 1211607284 |
| Principal investigator 1 | PFIZER INC. | $83.60 | 03/19/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775432 |
| Principal investigator 1 | OraSure Technologies Inc. | $82,850.00 | 03/12/2025 | Non-covered Recipient Entity Frontier Clinical Research | Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use | No dispute reported | 06/30/2026 | 1248792178 |
| Principal investigator 1 | ABBVIE INC. | $16,250.00 | 03/07/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202460113 |
| Principal investigator 1 | ABBVIE INC. | $3,581.55 | 03/06/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202457158 |
| Principal investigator 1 | Genentech, Inc. | $11,682.00 | 03/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607484 |
| Principal investigator 1 | Genentech, Inc. | $7,726.00 | 02/19/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607458 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,163.20 | 02/19/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192172408 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,500.00 | 02/14/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | A DOUBLE-BLIND, DOUBLE DUMMY, RANDOMIZED, PHASE 1B, NITROFURANTOIN CON | No dispute reported | 06/30/2026 | 1192170353 |
| Principal investigator 1 | Genentech, Inc. | $1,303.00 | 02/12/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607504 |
| Principal investigator 1 | ABBVIE INC. | $545.00 | 02/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202445216 |
| Principal investigator 1 | ABBVIE INC. | $5,551.20 | 02/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202445219 |
| Principal investigator 1 | Genentech, Inc. | $15,274.00 | 02/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607422 |
| Principal investigator 1 | Genentech, Inc. | $7,783.00 | 02/05/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607501 |
| Principal investigator 1 | Ardelyx, Inc. | $923.25 | 02/03/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838063 |
| Principal investigator 1 | Ardelyx, Inc. | $887.50 | 02/03/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838066 |
| Principal investigator 1 | Ardelyx, Inc. | $687.50 | 02/03/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | AN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OLD | No dispute reported | 06/30/2026 | 1247838070 |
| Principal investigator 1 | Eli Lilly and Company | $756.52 | 01/31/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | No dispute reported | 06/30/2026 | 1187883728 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13,594.00 | 01/30/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH, LLC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190310492 |
| Principal investigator 1 | Eli Lilly and Company | $17,093.00 | 01/27/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | No dispute reported | 06/30/2026 | 1187881660 |
| Principal investigator 1 | Genentech, Inc. | $7,783.00 | 01/22/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607445 |
| Principal investigator 1 | Genentech, Inc. | $90.00 | 01/17/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607437 |
| Principal investigator 1 | Genentech, Inc. | $396.00 | 01/14/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607407 |
| Principal investigator 1 | Genentech, Inc. | $192.00 | 01/14/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607453 |
| Principal investigator 1 | Genentech, Inc. | $184.00 | 01/14/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211607493 |
| Principal investigator 1 | PFIZER INC. | $1,574.12 | 01/09/2025 | Non-covered Recipient Entity Frontier Clinical Research LLC | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228801527 |
| Principal investigator 1 | OraSure Technologies Inc. | $3,750.00 | 01/08/2025 | Non-covered Recipient Entity Frontier Clinical Research | Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use | No dispute reported | 06/30/2026 | 1248792172 |
| Principal investigator 1 | OraSure Technologies Inc. | $18,750.00 | 01/08/2025 | Non-covered Recipient Entity Frontier Clinical Research | Human Factors and Clinical Validation of the Orasure InteliSwab COVID-19+Flu A&B Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use | No dispute reported | 06/30/2026 | 1248792176 |
| Principal investigator 1 | ABBVIE INC. | $1,104.40 | 01/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | M21-572 - A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation | No dispute reported | 06/30/2026 | 1202435062 |
| Principal investigator 1 | ABBVIE INC. | $2,180.25 | 01/02/2025 | Non-covered Recipient Entity FRONTIER CLINICAL RESEARCH LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202435134 |